Cabaletta Bio Reports Strong Rese-cel Data Across Autoimmune Portfolio, Advances Registrational Plans

summarizeSummary

Cabaletta Bio released encouraging clinical data for its rese-cel therapy in autoimmune diseases, outlining plans for registrational studies in systemic sclerosis and myositis, and advancing its preconditioning-free program.

check_boxKey Events

• Positive Clinical Data for Myositis

  83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint, with responses maintained for up to 1.5 years. The first juvenile dermatomyositis patient also showed a moderate response maintained for 32 weeks.

• Systemic Sclerosis Advances to Registrational Program

  Systemic Sclerosis (SSc) is announced as a second pivotal indication, with a single-arm registrational study for SSc-associated interstitial lung disease anticipated to start in 4Q26.

• Encouraging PC-Free Lupus Findings

  Initial data from preconditioning-free (PC-free) rese-cel in lupus patients showed deep B cell depletion in one of two patients, suggesting potential for broader patient access and improved experience.

• Clear Regulatory Pathway

  The company plans a Biologics License Application (BLA) submission for adult and juvenile dermatomyositis in 2H27 and will report topline data from the DM/ASyS registrational cohort in mid-2027.

auto_awesomeAnalysis

Cabaletta Bio announced comprehensive positive clinical data for its rese-cel therapy across multiple autoimmune diseases, including dermatomyositis, systemic sclerosis, and lupus. The data shows high response rates and a favorable safety profile, supporting the company's strategy to advance rese-cel into registrational trials. This update is critical for the company's long-term prospects, especially following recent dilutive financing and a 'going concern' warning, as it provides a clear path towards potential regulatory submissions and commercialization.